Comparison of work productivity losses in the United States among employees with COVID-19 at high-risk of severe disease who were untreated or treated with nirmatrelvir/ritonavir

Within this sample of high-risk employees, NMV/r therapy was associated with reduced societal burdens following COVID-19 infection.

Authors

Mohammad A. Chaudhary (ORCID: https://orcid.org/0000-0001-6552-9093)
Emmanuel F. Drabo (ORCID: https://orcid.org/0000-0001-7470-4391)
Gurinder Sidhu (ORCID: https://orcid.org/0000-0003-2531-7058)
M. Fernandez (ORCID: https://orcid.org/0000-0002-7361-333X)
Brenna L. Brady (ORCID: https://orcid.org/0000-0003-3210-806X)
Paul Cislo
Frank R. Ernst (ORCID: https://orcid.org/0000-0001-6927-9765)
Ruth Mokgokong (ORCID: https://orcid.org/0000-0002-6278-4969)
Joseph C. Cappelleri (ORCID: https://orcid.org/0000-0001-9586-0748)
Kristin Evans (ORCID: https://orcid.org/0000-0003-0987-1745)